Metoprolol er
Searched over 200M research papers for "metoprolol er"
Summary
10 papers analyzed
These studies suggest that extended-release metoprolol succinate is effective and well-tolerated for hypertension in children, reduces mortality and morbidity in chronic heart failure, and is bioequivalent to reference formulations, but interactions with paroxetine can affect its beta-blockade and cardioselectivity.
Not a yes or no question
To use the Consensus Meter, try asking a simple yes or no question
Research summarized with Copilot
Beta20 papers analyzed
Metoprolol ER: Efficacy, Safety, and Clinical Applications
Introduction to Metoprolol ER
Metoprolol succinate extended-release (ER) is a beta-blocker commonly used to manage hypertension, heart failure, and other cardiovascular conditions. Its extended-release formulation ensures consistent drug delivery over a 24-hour period, enhancing patient compliance and therapeutic outcomes.
Efficacy in Hypertension Management
Blood Pressure Reduction in Children
A clinical trial evaluated the efficacy of ER metoprolol in hypertensive children aged 6 to 16 years. The study found that ER metoprolol significantly reduced systolic and diastolic blood pressure compared to placebo, with a dose-response relationship observed. The treatment was well-tolerated with no serious adverse events reported.
Combination Therapy with Felodipine
In hypertensive patients, combination therapy with ER metoprolol and felodipine has shown additive effects in lowering blood pressure. The combination was more effective than monotherapy with either drug alone, and low-dose combinations were as effective as high-dose monotherapy but better tolerated .
Role in Chronic Heart Failure
Mortality and Morbidity Benefits
ER metoprolol succinate has demonstrated significant benefits in patients with chronic heart failure. The MERIT-HF trial showed a 34% reduction in all-cause mortality and a 19% reduction in the combined endpoint of mortality plus all-cause hospitalizations. The therapy was well-tolerated, with a discontinuation rate similar to placebo. Additionally, economic analyses predict substantial cost savings due to reduced hospitalizations and improved survival.
Pharmacokinetics and Bioequivalence
Comparison of Generic and Brand Formulations
A study comparing the pharmacokinetics of brand-name and generic ER metoprolol formulations found similar area under the curve (AUC) and maximum concentration (Cmax) values. However, differences in time to maximum concentration (Tmax) were noted, which may affect drug effects on autonomic balance. Another study confirmed the bioequivalence of test and reference ER metoprolol tablets in healthy Chinese subjects under both fasting and fed conditions.
Interaction with Paroxetine
Research has shown that the CYP2D6 inhibitor paroxetine significantly increases the plasma concentrations of both immediate-release and extended-release metoprolol. This interaction could lead to greater beta-blockade and reduced cardioselectivity, highlighting the importance of monitoring when these drugs are co-administered.
Potential in Depression Management
Inhibition of Endoplasmic Reticulum Stress
ER metoprolol, along with N-acetylcysteine and escitalopram, has been shown to prevent depression-like behaviors in a rat model by inhibiting endoplasmic reticulum stress. This suggests a potential novel therapeutic target for major depressive disorder.
Conclusion
ER metoprolol succinate is a versatile and effective medication for managing hypertension and chronic heart failure, with additional potential benefits in depression management. Its extended-release formulation ensures consistent therapeutic effects, and it is generally well-tolerated across different patient populations. The drug's pharmacokinetic profile and interactions with other medications should be carefully considered to optimize treatment outcomes.
Sources and full results
Most relevant research papers on this topic
